Summary:
Study Summary:
Title: RSV and Influenza Vaccine for Adults ≥65 Years
Objective: This study aims to assess the safety, tolerability, and immune response of the Respiratory Syncytial Virus (RSV) vaccine, designed to protect against RSV, when administered alongside a high-dose, quadrivalent seasonal influenza vaccine. The study focuses on adults aged 65 years and older.
Why Participate:
- Contribute to Science: By participating, you'll contribute to the development of a new vaccine that could help protect older adults against RSV.
- Safety and Tolerability: The study assesses the safety and how well the vaccines are tolerated.
- Age Group: If you're 65 years or older, this study is specifically designed for your age group.
What to Expect:
- Vaccination: You'll receive both the RSV vaccine and a high-dose seasonal influenza vaccine.
- Observation: The study is observer-blind, meaning some participants may receive a placebo, while others receive the vaccines.
- Monitoring: You'll be closely monitored throughout the study to track your immune response and any potential side effects.
Qualified Participants Must:
• Be at least 65 years of age
•
No vaccinations of any kind within the last 28 days
•
No flu vaccine within the last 6 months
•
Never had a vaccine for RSV
Qualified Participants May Receive:
- Compensation for time and travel
- Free RSV and Flu vaccines
- Free study-related lab work